Recent News

• 06.12.2025 - Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
• 06.12.2025 - Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
• 05.27.2025 - Aptose Announces Results from Annual and Special Meeting of Shareholders
• 05.27.2025 - Aptose Announces Results from Annual and Special Meeting of Shareholders
• 05.20.2025 - Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
• 05.20.2025 - Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
• 05.14.2025 - Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
• 05.05.2025 - Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Recent Filings

• 06.12.2025 - EX-99.1 EX-99.1
• 06.12.2025 - 8-K Current report
• 05.28.2025 - EX-99.1 EX-99.1
• 05.28.2025 - 8-K Current report
• 05.20.2025 - 8-K Current report
• 05.20.2025 - EX-99.1 EX-99.1
• 05.14.2025 - 8-K Current report
• 05.14.2025 - EX-99.1 EX-99.1
• 05.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.08.2025 - EX-99.1 EX-99.1